Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Enlivex (ENLV) Stock Price & Analysis
367 Followers
ENLV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $4.59
Previous Close$1.42
Volume4.01K
Average Volume (3M)180.28K
Market Cap
$26.41M
Enterprise Value-$19.64M
Total Cash (Recent Filing)$50.24M
Total Debt (Recent Filing)$4.19M
Price to Earnings (P/E)-0.9
Beta1.46
Next Earnings
May 24, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding18,598,555
10 Day Avg. Volume43,616
30 Day Avg. Volume180,279
Standard Deviation0.29
R-Squared0.05
Alpha-0.00048
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.13
Forecast
1Y Price Target
$7.00Price Target Upside392.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Enlivex News
PremiumCompany Announcements
Enlivex Therapeutics: Promising Trial Results for Allocetra
PremiumCompany Announcements
Enlivex Therapeutics Launches Knee Osteoarthritis Trial
PremiumCompany Announcements
Enlivex Advances Osteoarthritis Trial in Denmark
PremiumCompany Announcements
Enlivex’s Allocetra™ Shows Promise in Sepsis TrialBulls Say, Bears Say
Bulls Say
Clinical Trials AdvancementThe Phase 1/2 trial in knee osteoarthritis is progressing, with primary measurements set to evaluate improvements in joint pain and function, offering hope for better patient outcomes.
Market PotentialEnlivex's planning for a follow-on study in UTI-related sepsis indicates a strategic move to target a large market with a high unmet medical need.
Regulatory MilestoneRegulatory approval in Denmark for the knee osteoarthritis clinical program marks a significant step forward in the trial's international expansion.
Bears Say
Clinical Trial OutcomesMid-stage sepsis trial yields mixed results, indicating uncertainty in the drug's effectiveness.
Drug Development RisksImbalances in patient attributes between treatment and control groups present challenges in assessing the drug's efficacy.
Regulatory ApprovalAnalyst lowers price target due to a reduced probability of drug approval in the sepsis indication.
---
Ownership Overview
0.00%
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.15 and its highest was $4.59 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Currently, no data Available
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 24, 2024 which is in 3 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on Nov 20, 2023. The company reported -$0.32 earnings per share for the quarter, the consensus estimate of -$0.32 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate is -$0.25.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 18,598,555 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.32 in its last earnings report, expectations of -$0.32. Following the earnings report the stock price went down -1.724%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Among the largest hedge funds holding Enlivex Therapeutics Ltd’s share is ARK Investment Management LLC. It holds Enlivex Therapeutics Ltd’s shares valued at N/A.
---
Enlivex Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (392.89% Upside)
$7.00 (392.89% Upside)
Hedge Fund Trend
Decreased
By 331.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
-45.55%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
---
ENLV Stock 12 Month Forecast
Average Price Target
$7.00
▲(392.89% Upside)
Technical Analysis
Best Analysts Covering ENLV
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-31.44%
reiterated a buy rating 29 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -31.44% per trade.
---